Search
- Jan 9
Galápagos CEO Paul Stoffels on the company's $3.8B cash balance and decentralized CAR-T program
Paul Stoffels describes how his company's decentralized CAR-T process is designed to have a shorter 'brain-to-vein' time.
Also look for unique social pages for BiotechTV U.
#1. Ultragenyx's Emil Kakkis on Angelman syndrome data, rare disease treatment modalities, and more
#2. The CEO of Madrigal on the launch of Rezdiffra for NASH liver disease
#3. Sutro Biopharma's CEO on ADCs, non-cell protein synthesis, and more
#4. Verve Therapeutics' CEO on today's gene editing clinical trial pause
#5. Daphne Zohar on becoming the CEO of Seaport Therapeutics and a $100M series A